Amneal Pharmaceuticals Receives FDA Approval for Generic Omnipaque Version
ByAinvest
Thursday, Nov 13, 2025 11:31 pm ET1min read
AMRX--
GEHC--
Amneal Pharmaceuticals has received FDA approval for its generic version of GE Healthcare's Omnipaque (iohexol) injection. The product, iohexol injection (300 mg Iodine/mL), will be launched in Q1 2026 and is indicated for use in imaging procedures for adults and pediatric patients aged two weeks and older. The product had annual US sales of approximately $652 million in the 12 months ended September 2025.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet